Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance - CNBC

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

You are being redirected to the original discussion. Please continue if you want to read the full post.

Continue to original article

You will be redirected in 3 seconds.